Accepting applications until August 1

City of Hope Intensive Course in Genomic Cancer Risk Assessment

Accepting applications until August 1

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

F Marmé, M Martin, M Untch, et al. ESMO Open. 2024 Jun;9(6):103466

The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compare... Read More